Inoculations are the number one weapon against the Covid-19, but not everyone can access them equally.
For a second time this year, members of the World Trade Organization failed to find a compromise on vaccination patent waivers.
South Africa, India and the U.S., backed by dozens of countries, are leading calls for the suspension of intellectual property rights on several jabs.
They say it would help increased production worldwide and end the pandemic much quicker.
But drug companies and some European nations are against it, saying the waiver may not have the intended effects?
So is there a middle ground?
Presenter: Bernard Smith
Guests:
Brook Baker, Professor of Law at the Northeastern University.
Azeddine Ibrahimi, head of Biotechnology Lab at the Rabat Medical School.
Paul Torremans, Professor of Intellectual Property Law at the University of Nottingham.
- Follow us on Twitter: https://twitter.com/AJEnglish/
- Find us on Facebook: https://www.facebook.com/aljazeera/
- Check our website: https://www.aljazeera.com/
For a second time this year, members of the World Trade Organization failed to find a compromise on vaccination patent waivers.
South Africa, India and the U.S., backed by dozens of countries, are leading calls for the suspension of intellectual property rights on several jabs.
They say it would help increased production worldwide and end the pandemic much quicker.
But drug companies and some European nations are against it, saying the waiver may not have the intended effects?
So is there a middle ground?
Presenter: Bernard Smith
Guests:
Brook Baker, Professor of Law at the Northeastern University.
Azeddine Ibrahimi, head of Biotechnology Lab at the Rabat Medical School.
Paul Torremans, Professor of Intellectual Property Law at the University of Nottingham.
- Follow us on Twitter: https://twitter.com/AJEnglish/
- Find us on Facebook: https://www.facebook.com/aljazeera/
- Check our website: https://www.aljazeera.com/
Sign in or sign up to post comments.
Be the first to comment